卫信康(603676) - 卫信康投资者关系活动记录表（2024-11-05）

Group 1: Company Overview and Mission - The company adheres to the corporate spirit of "Responsibility, Sharing, Integrity, Innovation" and focuses on the mission of "Caring for Life, Maintaining Health" [2] - The company aligns with national policies and industry development directions, leveraging its R&D technology advantages to meet clinical needs [2] Group 2: Financial Performance - In the first three quarters of 2024, the company achieved operating revenue of 994 million yuan, a decrease of 6.30% year-on-year [2] - The net profit attributable to shareholders of the listed company was 243 million yuan, an increase of 15.71% year-on-year [2] Group 3: R&D Investment - The R&D expenses for the first three quarters of 2024 amounted to 76.76 million yuan, an increase of 9.39% compared to the same period last year [2] - The company has received clinical trial approval for two products and has obtained drug registration for four products, indicating a strong commitment to R&D innovation [2]